Loading stock data…
NXTC
$9.36+0.15 (+1.63%)
Market ClosedLast close May 1
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NextCure, Inc. in the Healthcare sector is trading at $9.36. The stock is currently 41% below its 52-week high of $15.74, remaining 2.9% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why NXTC maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.36
Potential Upside
5%
Whystock Fair Value$9.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$42.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-159.81%
Volume
Today's trading volume
90,078
Recent News
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Companies Like NextCure (NASDAQ:NXTC) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, although...
NextCure and Simcere partner to develop SIM0505 for solid tumours
The SIM0505 employs a unique epitope which enhances tumour binding.
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients […]